BPC-157, or body protection compound 157, is a synthetic pentadecapeptide, a 15-amino-acid chain, that is derived from a portion of the naturally occurring Body Protection Compound found in human gastric juice. It was identified and characterised by researchers at the University of Zagreb, led by Professor Predrag Sikiric, who have published over 100 peer-reviewed studies on its properties. What makes BPC-157 remarkable in the animal literature is the breadth of tissues it appears to heal, gut mucosa, tendons, muscle, bone, nerve, and blood vessels, and the speed with which it appears to act compared to untreated controls.
The Animal Evidence
The animal research on BPC-157 is extensive, with studies demonstrating accelerated healing of rat Achilles tendon transection, repair of rat superior mesenteric artery, regeneration of damaged rat colonic anastomoses, neuroprotection in models of spinal cord injury, and reduced gastric ulceration in rat models of NSAID-induced damage. A study published in the Journal of Orthopedic Research found that rats treated with BPC-157 after Achilles tendon transection showed significantly superior tendon healing at 2 weeks compared to untreated controls. Research in the European Journal of Pharmacology demonstrated that BPC-157 promotes angiogenesis, the formation of new blood vessels, which may explain its broad tissue-healing effects across different tissue types.
The Proposed Mechanisms
BPC-157 appears to work through several intersecting mechanisms. It promotes angiogenesis through upregulation of VEGF and its receptors, increasing blood supply to healing tissues. It activates the nitric oxide pathway, which is central to both vasodilation and tissue repair signalling. It modulates the serotonergic and dopaminergic systems, which may explain its observed effects on gut motility and mood in animal models. It also appears to counteract the tissue-damaging effects of non-steroidal anti-inflammatory drugs and corticosteroids, which has led to its use in animal models of NSAID-induced gut damage.
The Human Evidence
This is where caution is warranted. As of mid-2027, published human clinical trial data on BPC-157 is extremely limited. One phase II clinical trial was registered for inflammatory bowel disease treatment using an oral form of BPC-157, but published results are not yet available. The human pharmacokinetic data is also limited. The mechanism by which BPC-157 is absorbed, distributed, and eliminated in humans is not fully characterised. Those using BPC-157 without published human trial data are effectively self-experimenting ahead of the formal clinical evidence.
Legal and Regulatory Status
BPC-157 is not a licensed medicine in the United Kingdom or the European Union. It is not approved as a food supplement. Its legal status for personal use falls into a grey area. It is not a scheduled controlled substance in the UK, meaning its possession is not illegal, but its sale for human consumption is not authorised. Those considering its use should be aware of this regulatory context and should source only from suppliers who provide third-party purity testing, as the unregulated supply chain carries risks of contamination and misdosing.
Sources
- Sikiric, P., et al. (2013). Stable gastric pentadecapeptide BPC-157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design, 17(16), 1612-1632.
- Gwyer, D., et al. (2019). Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell and Tissue Research, 377(2), 153-159.
- Chang, C.H., et al. (2011). The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth. Acta Physiologica, 201(4), 491-503.
- Tkalcevic, V.I., et al. (2007). Enhancement by PL 14736 of granulation and collagen organisation in healing wounds. European Journal of Pharmacology, 570(1-3), 212-221.
- Sikiric, P., et al. (2018). Brain-gut axis and pentadecapeptide BPC 157. Current Neuropharmacology, 14(8), 857-865.